scorecardresearchMarksans Pharma Share Price Live NSE, BSE, Today - Marksans Pharma Stock
Mintgenie
Asian Paints2,844.60-16.95 (-0.59%)
Axis Bank1,130.052.70 (0.24%)
Bajaj Finance6,729.85-564.05 (-7.73%)
Bajaj Finserv1,597.10-58.70 (-3.55%)
Bharti Airtel1,325.50-10.45 (-0.78%)
HCL Technologies1,476.80-26.85 (-1.79%)
HDFC Bank1,509.75-0.90 (-0.06%)
Hindustan Unilever2,221.50-9.50 (-0.43%)
ICICI Bank1,107.15-5.90 (-0.53%)
ITC439.952.45 (0.56%)
Indusind Bank1,445.85-50.30 (-3.36%)
Infosys1,430.15-8.25 (-0.57%)
Kotak Mahindra Bank1,608.40-34.60 (-2.11%)
Larsen & Toubro3,602.30-48.35 (-1.32%)
Mahindra & Mahindra2,055.00-40.55 (-1.94%)
Maruti Suzuki India12,687.05-219.05 (-1.70%)
NTPC355.75-2.55 (-0.71%)
Nestle India2,483.80-78.90 (-3.08%)
Power Grid Corporation Of India292.60-0.50 (-0.17%)
Reliance Industries2,903.00-15.40 (-0.53%)
State Bank Of India801.40-11.20 (-1.38%)
Sun Pharmaceutical Industries1,504.25-16.30 (-1.07%)
Tata Consultancy Services3,825.00-26.85 (-0.70%)
Tata Motors999.35-1.45 (-0.14%)
Tata Steel165.85-1.75 (-1.04%)
Tech Mahindra1,277.4587.35 (7.34%)
Titan Company3,584.4011.75 (0.33%)
Ultratech Cement9,735.3551.75 (0.53%)
Wipro464.653.65 (0.79%)

Marksans Pharma

BSE: 524404 | NSE: MARKSANS | ISIN: INE750C01026 | SECTOR: Biotechnology & Drugs

₹172.20 5.30 (3.18%)

26 Apr 2024, 10:25 (IST)

  • Open

    166.95

  • High

    173.85

  • Low

    166.25

  • Prev Close

    166.90

  • P/E

    -

  • Median P/E

    -

  • P/B

    -

  • Median P/B

    -

  • Market Cap

    78.03B

  • Volume

    182.45K

  • Vol. (20 day Avg.)

    0

  • PEG

    -

  • Div.Yield

    -

  • Bid

    -

  • Ask

    -
View all metrics

Company Description

  • Biotechnology & Drugs

  • BSE

    524404

  • NSE

    MARKSANS

  • ISIN

    INE750C01026

Marksans Pharma Limited is an India-based pharmaceutical company. The Company is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. The Company produces goods across various therapeutic areas, such as pain management, cough and cold, cardiovascular and central nervous system, anti-diabetic, gastrointestinal, hormonal treatment, and anti-allergic, among others. The Company operates four manufacturing facilities across India, the United Kingdom and the United States. The Company manufactures oral solid tablets, soft gelatin capsules and hard capsules in Goa. It also manufactures non-sterile liquids, ointments and powder products and caters to the United Kingdom, West Africa and the Middle East, which is located in the United Kingdom. The Company has spread its facility to over 7000 square meters and manufactures tablets and capsules in the United States.

Company Officers

  • Mark Saldanha

    Executive Chairman of the Board, Managing Director

  • Jitendra Sharma

    Chief Financial Officer

  • Harshavardhan Panigrahi

    Compliance Officer, Company Secretary and Legal Manager

  • Varddhman Jain

    Whole Time Director

  • Sandra Saldanha

    Whole Time Director